{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-25-000021","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.193408+00:00","generated_at":"2026-05-24T06:52:12.885752+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"AEON Biopharma advances ABP-450 biosimilar program, secures $20M funding","bullets":["Pursuing 351(k) biosimilar pathway for ABP-450 with BOTOX as reference product for all therapeutic indications.","Initiated primary analytical studies in Q4 2024; plans BPD Type 2a meeting with FDA in H2 2025.","Closed $20M public offering in Jan 2025; ~89% of Series B warrants exercised as of March 21, 2025.","No specific FY2024 financial results disclosed in the press release; focus on development and funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-25-000021","json":"https://secwatch.observer/filing/0001837607-25-000021.json","markdown":"https://secwatch.observer/filing/0001837607-25-000021.md","text":"https://secwatch.observer/filing/0001837607-25-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000021/0001837607-25-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000021/aeon-20250324x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:52:12.885752+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}